共 50 条
- [1] A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid TumorsBLOOD, 2022, 140 : 12024 - 12025Smith, Stephen D.Starodub, AlexanderStevens, Don A.Shastri, AditiPorcu, PierluigiFeldman, TatyanaEwesuedo, ReggieDeSavi, ChrisDey, JoyotiAgarwal, SagarDonohue, SeanPerea, RachelleKlaus, ChristineGollob, Jared
- [2] Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid TumorsBLOOD, 2023, 142Shastri, AditiFeldman, Eric J.Starodub, Alexander N.Feldman, TatyanaRodriguez, Cristina P.Epstein-Peterson, Zachary D.Stevens, Don A.Olszewski, Adam J.Huen, Auris O.Porcu, PierluigiReneau, John C.Barta, Stefan K.Marchi, EnricaMattour, Ahmad H.Pinter-Brown, Lauren C.Perea, RachelleDonohue, SeanDey, JoyotiAgarwal, SagarKarnik, RahulGollerkeri, AshwinGollob, JaredSmith, Stephen D.
- [3] Phase 1 study of KT-413, a targeted protein degrader, in adult patients with relapsed or refractory B-cell non-Hodgkin lymphomaJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Stevens, Don A.Ewesuedo, ReginaldMcDonald, AliceAgarwal, SagarHenrick, PatrickPerea, RachelleGollerkeri, AshwinGollob, Jared
- [4] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumorsPEDIATRIC BLOOD & CANCER, 2021, 68 (11)Meany, Holly J.Widemann, Brigitte C.Hinds, Pamela S.Bagatell, RochelleShusterman, SuzanneStern, EmilyJayaprakash, NaliniPeer, Cody J.Figg, William D.Hall, O. MorganSissung, Tristan M.Kim, AerangFox, ElizabethLondon, Wendy B.Rodriguez-Galindo, CarlosMinturn, Jane E.Dome, Jeffrey S.
- [5] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (03) : 9 - 10Barr, Paul M.Hill, Brian T.Ma, ShuoBaran, Andrea M.Bui, AndrewMeacham, Philip J.Morrison, AshleyLiesveld, Jane L.Mulford, Deborah A.Sportelli, PeterMiskin, Hari P.Weiss, Michael S.Friedberg, Jonathan W.Zent, Clive S.
- [6] Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaLEUKEMIA & LYMPHOMA, 2012, 53 (03) : 417 - 423Wendtner, Clemens-MartinHillmen, PeterMahadevan, DarukaBuehler, AndreasUharek, LutzCoutre, StevenFrankfurt, OlgaBloor, AdrianBosch, FrancescFurman, Richard R.Kimby, EvaGribben, John G.Gobbi, MarcoDreisbach, LukeHurd, David D.Sekeres, Mikkael A.Ferrajoli, AlessandraShah, SheetalZhang, JennieMoutouh-de Parseval, LaureHallek, MichaelHeerema, Nyla A.Stilgenbauer, StephanChanan-Khan, Asher A.
- [8] Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin LymphomaBLOOD, 2022, 140 : 12143 - 12144Lue, Jennifer KimberlyStevens, Don A.Williams, Michael E.Westin, JasonEwesuedo, ReggieMcDonald, AliceAgarwal, SagarHenrick, PatrickPerea, RachelleGollob, Jared
- [9] Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Meany, Holly JaneDome, JeffreyHinds, Pamela S.Bagatell, RochelleShusterman, SuzanneWidemann, Brigitte C.Stern, EmilyLondon, Wendy B.Kim, AeRangFox, ElizabethRodriguez-Galindo, CarlosMinturn, Jane E.
- [10] A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemiaLEUKEMIA, 2023, 37 (04) : 835 - 842Ryan, Christine E.Brander, Danielle M.Barr, Paul M.Tyekucheva, SvitlanaHackett, Liam R.Collins, Mary C.Fernandes, Stacey M.Ren, YueZhou, YingluMcDonough, Mikaela M.Walker, Heather A.McEwan, Monica R.Abramson, Jeremy S.Jacobsen, Eric D.LaCasce, Ann S.Fisher, David C.Brown, Jennifer R.Davids, Matthew S.